Optellum Expands AI Lung Cancer Diagnostics to 250 Sites

Optellum, a medical technology leader based in Oxford and Houston, has reached a significant milestone: its AI-powered lung cancer diagnostic platform is now active in over 250 clinical sites worldwide.

At the heart of this growth is the Virtual Nodule Clinic (VNC), an innovative software that assists clinicians by analyzing CT scans to identify and assess lung nodules.

Using advanced 'Lung Cancer Prediction' AI, the system assigns a malignancy risk score to nodules within seconds and utilizes natural language processing to ensure no incidental findings are missed.

As the first FDA-cleared and CE-marked tool of its kind, Optellum has already processed over 3 million patient cases.

The company is now evolving its technology into 'LungOS®,' a comprehensive operating system for thoracic care that integrates diagnostic precision with clinical workflows.

Through strategic partnerships with major entities like GE HealthCare and the NHS, Optellum is transforming lung cancer detection from a manual process into a highly efficient, AI-augmented standard of care.

This expansion signals a major step forward in global medical technology, moving AI from experimental research into essential, life-saving hospital practice.